NASDAQ$IRON
Disc Medicine Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Disc Medicine reported financial results for Q1 2024 and provided business update.
Disc Medicine reported a net loss of $26.9 million for the quarter ended March 31, 2024. The company's cash and cash equivalents totaled $342.6 million, expected to fund operations well into 2026.
- Top-line results from the AURORA phase 2 study of bitopertin in erythropoietic porphyrias (EPP) were presented in April 2024.
- Additional analyses from BEACON and AURORA are on track to be delivered in Q2 2024.
- Updated data from the phase 1b/2 study of DISC-0974 in anemia of myelofibrosis (MF) and initial single-ascending dose (SAD) data from the phase 1 study of DISC-3405 in healthy volunteers are planned for presentation in Q2 2024.
- The company ended Q1 2024 with $343M in cash and cash equivalents, providing runway well into 2026.
Headline financials
Revenue & EPS history
Disc Medicine · Revenue · Quarterly
$0
Forward guidance
Disc Medicine anticipates several milestones and data releases in the near future, while also acknowledging the inherent risks and uncertainties in drug development and clinical trials.
Tailwinds
- Additional analyses from the AURORA and BEACON trials to be presented in Q2 2024.
- Updated phase 1b/2 data from DISC-0974 in anemia in MF patients will be presented in Q2 2024.
- Initial pharmacokinetic and pharmacodynamic data from SAD cohorts expected to be presented in Q2 2024.
- Regulatory interactions to define optimal registrational endpoints moving forward in EPP expected to occur in the second half of 2024.
- Cash and cash equivalents are expected to fund operational plans well into 2026.
Headwinds
- The adequacy of Disc’s capital to support its future operations and its ability to successfully initiate and complete clinical trials.
- The difficulty in predicting the time and cost of development of Disc’s product candidates.
- The risk that the results of Disc’s clinical trials may not be predictive of future results in connection with future studies or clinical trials and may not support further development and marketing approval.
- Enrollment timelines of both the BEACON and AURORA studies may not necessarily be predictive of future enrollment timelines.
- New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q1 2024
-0.4%
Avg return
Earnings day
-1.7%
Avg return
5 days after
+3.9%
Avg return
30 days after
56%
10 / 18 earnings
Positive
+14.6%
Q3 2021
Best reaction
-12.4%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +1.3% | -3.8% | -10.2% | |
| Q3 2025 | -1.6% | -2.5% | +5.6% | |
| Q2 2025 | -3.4% | +0.1% | +3.0% | |
| Q1 2025 | +2.3% | +3.8% | +14.1% | |
| Q4 2024 | +0.1% | +1.6% | -3.9% | |
| Q3 2024 | -5.3% | -10.7% | -3.5% | |
| Q1 2024 | +3.5% | +8.5% | +33.3% | |
| Q4 2023 | -8.7% | -9.2% | -56.8% | |
| Q3 2023 | +1.7% | +8.1% | +27.8% | |
| Q2 2023 | +0.3% | +1.9% | -1.2% | |
| Q1 2023 | +0.6% | +1.8% | +47.6% | |
| Q4 2022 | -0.6% | +0.7% | +48.4% | |
| Q3 2022 | -0.6% | -4.7% | -2.4% | |
| Q2 2022 | -12.4% | -10.9% | -31.8% | |
| Q1 2022 | +3.6% | +10.1% | +8.6% | |
| Q4 2021 | -3.2% | -7.7% | -11.0% | |
| Q3 2021 | +14.6% | -5.6% | -12.6% | |
| Q2 2021 | +0.2% | -12.8% | +15.3% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro